论文部分内容阅读
肾细胞癌是泌尿系统肿瘤中常见的恶性肿瘤,发病率约5～10/10万。转移性肾细胞癌在以细胞因子为基础的治疗失败后,尚无明确的二线治疗措施。随着对乏氧诱导因子(hypoxia-inducible factor,HIF)相关蛋白的研究,转移性肾细胞癌分子靶向治疗研究成为热点。本文综述较有前景的靶向药物,包括Bevacizumab(贝伐单抗)、Sorafenib(索拉非尼)、Sunitinib(舒尼替尼)、AG-013736、Vatalanib(PTK787)、Thalidomide(沙利度胺)及Temsirolimus(CCI-779)。
Renal cell carcinoma is a common malignant tumor in urinary system tumors, the incidence of about 5-10 / 100,000. There is no clear second-line treatment for metastatic renal cell carcinoma after cytokine-based treatment fails. With the study of hypoxia-inducible factor (HIF) -related proteins, molecular targeted therapy of metastatic renal cell carcinoma has become a hot spot. This article reviews the more promising targeted drugs including Bevacizumab, Sorafenib, Sunitinib, AG-013736, Vatalanib (PTK787), Thalidomide ) And Temsirolimus (CCI-779).